Notes on Certificate of Analysis, Lab Standards, and Supplement Quality

Certificate of Analysis and Supplement Quality: Key Concepts

  • CoA limitations and trust issues

    • We cannot assume the information on a certificate of analysis (CoA) is fully accurate or complete.

    • ConsumerLab and other organizations have found CoAs to be sometimes inaccurate or bogus.

    • Key questions a CoA does not fully answer:

    • Does the product contain the correct materials, or could there be counterfeit or adulterated components?

    • Are there toxins, pesticides, or heavy metals present?

    • Does the product meet label claims?

    • Is the product stable or expired?

    • Were solvents removed appropriately during extraction? Are active components present?

    • Conclusion: A CoA does not by itself guarantee quality and purity, even though it would be ideal if we could trust CoAs completely.

  • Solvents in botanical extraction

    • Solvents can be liquids or gases used to extract or dissolve chemical constituents from botanicals.

    • Example: turmeric root; major constituent curcumin is extracted using a solvent.

    • Common solvents range widely (likely two to 300+ solvents exist); typical benign ones include water or certain alcohols, but many toxic solvents can be used.

    • Important regulatory point: the FDA does not require testing of solvents in supplement manufacturing.

    • If a company opts to remove solvents and test for them, that is not mandated by the FDA.

    • Implication: even an accurate CoA doesn’t ensure solvent residue has been tested or removed.

  • Evidence from regulatory investigations (value and limitations of CoAs)

    • 2015 New York Attorney General investigation across major retailers (Walmart, GNC, Target, Walgreens):

    • Samples: 78 samples across NY; Tests: 390 tests conducted.

    • Finding: 79 ext{%} of DNA tests did not match the labeled herbs (roughly four out of five products).

    • Examples cited:- A popular ginseng store-brand supposedly for endurance contained only powdered garlic and rice.

      • Ginkgo biloba product contained powdered radish, house plants, and wheat; label claimed wheat-free but contained wheat.

    • Canada (2013): 44 products from 12 companies tested; only 2 of 12 companies met label claims; DNA results showed fillers like rice and other plant matter.

    • Even professional brands are not immune:

    • Hexavalent chromium (a carcinogenic form of chromium) found in 3/6 chromium supplements tested from professional brands.

    • 3/20 protein powders and sports drinks had mislabeled sugars/carbs.

    • Lead found in 2/3 products.

    • Amazon impersonation case (02/2023): NOW Supplements and other brands found products being sold as impersonations of NOW on Amazon.

    • Impersonation labs located in Spain and Italy; counterfeit products with questionable ingredients were sold.

    • After discovery, brands pursued litigation; ongoing risk due to Amazon’s scale.

    • Practical takeaway: buying supplements on Amazon or through unknown retailers increases risk of counterfeit or substandard products; advise clients to avoid Amazon and use trusted channels (e.g., practitioner channels like Fullscript, brand direct accounts).

  • Case study: NOW example and lab testing insights

    • NOW investigative case: a consumer bought a NOW product from Amazon; capsules looked different from the practitioner-sourced version.

    • NOW performed internal testing and found labels missing details and the product containing non-beneficial fillers (e.g., rice/potato derivatives) rather than the intended actives.

    • This illustrates that even well-known brands can be affected by counterfeit distribution and labeling gaps when sold through third-party marketplaces.

  • Analytical methods and the risk of relying on CoA without testing

    • High-Performance Liquid Chromatography (HPLC) as a key laboratory method to profile extracts.

    • Example: St. John’s Wort extract:

    • Desired constituents: hypericin (one of the key mood-modulating compounds) and hyperforin.

    • Some extracts labeled as St. John’s Wort were found via HPLC to have much lower or missing hypericin/hyperforin peaks; instead, peaks for other compounds (e.g., quercetin, linked to antihistamine effects) dominated.

    • Implication: a product with an apparently clean CoA may still be ineffective for its labeled purpose if the active constituents are missing or misrepresented.

    • If a company lacks in-house testing capability, it remains dependent on CoAs and cannot independently verify the presence and concentration of key constituents.

  • Classification of supplement companies by lab capability and oversight

    • Categories 1–2 (most questionable): private labeling and contract manufacturing with little to no control over raw materials or testing.

    • Private labeling: company purchases finished products from external manufacturers and applies its own label.

    • Contract manufacturing: the brand provides a formula to a manufacturer but has little control over raw materials, testing, or supply chain.

    • Example concern: a private-label brand may switch sources or formulations without consistent quality control; Mercola is cited as a cautionary example of a private-label approach.

    • Categories 3–4 (better but still limited):

    • Category 3: brands that manufacture their own products but do not operate their own laboratory.

    • Category 4: brands with certified manufacturing but their laboratory is not ISO certified.

    • Category 5: GMP-certified manufacturing and ISO-certified laboratory.

    • Only one company in this category: NOW brand.

    • Features: robust lab testing and production controls; ISO-certified lab reflects adherence to high international standards.

    • Category 6: brands that produce some of their own raw materials, have an ISO-certified lab, are directly FDA inspected, and maintain GMP-certified manufacturing.

    • Only one company in this category: Biotics Research.

    • Notable distinction: Biotics has pursued pharmaceutical licensing in certain jurisdictions; in the U.S., a pharmaceutical license is not required for supplements, but Biotics’ licensing leads to more rigorous testing and FDA oversight (including frequent inspections).

    • Practical implication: higher category numbers generally indicate stronger lab controls and reliability, though no system is perfect.

  • ISO, GMP, FDA, and the reality of third-party testing claims

    • ISO = International Organization for Standardization; certification signals adherence to high, internationally recognized lab procedures.

    • GMP = Good Manufacturing Practice; indicates controlled manufacturing environments and processes.

    • FDA oversight exists but is relatively minimal in many cases: the FDA does not require the breadth of testing that some third-party labels imply.

    • Third-party testing (e.g., NSF, USP) is often cited by brands, but compliance with FDA standards is the baseline, and some labs may test only selectively.

    • Anecdotal concerns:

    • A conference anecdote cited a statement that FDA rules permit a product to meet three of five sensory criteria (e.g., botanical appearance, smell, taste) to be considered acceptable—illustrating potential gaps in regulatory rigor.

    • Some manufacturers reportedly test only every few months rather than every batch, raising questions about batch-to-batch consistency.

    • Takeaway: third-party claims do not guarantee safety or efficacy; robust testing and ISO/GMP/FDA oversight are more meaningful indicators of quality.

  • Whole food supplements: benefits, limitations, and lab considerations

    • Question: are whole food-based supplements inherently better?

    • Key considerations:

    • Do these products have a laboratory to test for heavy metals, solvents, contaminants, and other residues?

    • Do they impose stricter contaminant limits than standard synthetic supplements?

    • Critical caveat: whole food supplements are often not provided in therapeutic doses; they frequently mimic food-level dosages rather than providing pharmacologically active levels.

    • Practical implication: for clients needing therapeutic outcomes, whole food supplements may be less cost-effective and less reliable for achieving dose-specific effects.

  • Practical guidance for practitioners and clients

    • Avoid purchasing supplements on Amazon or from unknown major retailers; seek trusted distribution channels (e.g., practitioner channels, Fullscript, direct brand accounts).

    • Encourage clients to evaluate brand quality using lab capabilities rather than relying solely on CoA or price.

    • Seek brands with clear GMP and ISO certifications, direct FDA oversight where possible, and transparent laboratory practices.

    • When possible, verify whether a company tests every batch versus only intermittently; inquire about specific tests conducted (heavy metals, solvents, contaminants, solubility, stability, expiry).

    • Consider whether the brand performs in-house testing or relies on external contract labs; assess the reliability of those labs (e.g., ISO certification, accreditation).

    • For private labeling or contract manufacturing brands, exercise caution about batch-to-batch consistency and raw material sourcing controls.

  • Takeaways on quality assurance and ethics

    • CoA alone is insufficient as sole evidence of product quality.

    • Regulators and independent assessments reveal that substandard or counterfeit products can appear legitimate on paper.

    • Consumers and practitioners should prioritize laboratories with ISO certification, GMP-compliant manufacturing, and direct FDA oversight when evaluating brands.

    • The ongoing counterfeit and mislabeling problem, including across high-profile retailers and marketplaces, necessitates vigilance in sourcing and ongoing testing beyond the CoA.

  • Quick reference: key numerical anchors from the transcript

    • NY AG (2015): 78 samples, 390 tests; 79 ext{%} DNA tests did not match labeled herbs.

    • Canada (2013): 44 products, 12 companies; only 2/12 met label claims; 10/12 did not.

    • Professional brands: hexavalent chromium found in 3/6 chromium supplements; lead found in 2/3 protein powders.

    • Amazon impersonation incident: NOW and others affected; investigations traced to facilities in Spain and Italy.

    • St. John’s Wort HPLC example: the expected peaks for hypericin and hyperforin were not present in a subpar extract; instead, peaks for other compounds (e.g., quercetin) dominated, indicating misrepresentation of active constituents.

    • ISO and lab leadership: Category 5 (NOW) has GMP manufacturing + ISO-certified lab; Category 6 (Biotics) has own raw materials, ISO lab, direct FDA inspections, and GMP manufacturing; Biotics cited as example with frequent FDA inspections (e.g., 278 inspections in a year).

    • FDA regulatory caveat: some products claim third-party testing, but FDA standards are minimal; a statement encountered suggested that “three out of five criteria” might be sufficient under some interpretations, underscoring potential loopholes in regulation.

  • Practical implications for exam-style understanding

    • CoA reliability is context-dependent; it should be supplemented with lab capabilities, batch testing, and supply-chain controls.

    • Understanding solvent use and testing is critical: FDA does not mandate solvent testing, so solvent residues can vary by manufacturer.

    • Real-world evidence (investigations by NY AG, Canadian studies, and counterfeit cases) demonstrates the risk of adulteration and label non-compliance in both retail and professional products.

    • Distinguishing among company categories (1–6) helps assess risk and inform sourcing decisions.

    • The distinction between whole food supplements and conventional supplements has practical implications for dosage, therapeutic outcomes, and cost.

  • Final synthesis

    • A robust approach to supplement quality requires more than a CoA: it requires trustworthy lab testing (preferably ISO-certified labs and GMP manufacturing with FDA oversight), transparent supply chains, scrutiny of raw material sourcing, and careful avoidance of high-risk distribution channels (e.g., unvetted marketplaces).

    • Clinicians should educate clients about these issues and guide them toward brands with demonstrated testing rigor and traceability, rather than relying on claims of third-party testing alone or on CoAs alone.